<i id='0A5275B557'><strike id='0A5275B557'><tt id='0A5275B557'><pre id='0A5275B557'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Duchenne breakthrough therapy leaves behind pioneering families 
2 million sign 
Trump demands the U.S. pay no more for drugs than other countries … again 
1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates 
Moonlake's readout produced a cash windfall. Risks remain 
Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle 
Heart attack and stroke risk calculators need revising 
Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources 
Medical leaders decry Supreme Court decision on affirmative action 
Teacher posts viral 'school supply rant' with advice for parents
Trump demands the U.S. pay no more for drugs than other countries … again 
Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS 
The high cost of giving birth even with insurance 
5 wounded, 2 critically, in Michigan shopping center shooting 
The cancer drug shortage isn’t new — and neither are the solutions 
